Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545433 | 0.86 | XDH (0.48) | XDHSGMS2PPIAFNTAFNTB | |
| SCHEMBL5544745 | 0.80 | XDH (0.49) | XDHSGMS2PPIAFNTAFNTB | |
| SCHEMBL5545418 | 0.78 | PPIA (0.49) | PPIAFNTAFNTBPGGT1B | |
| SCHEMBL5546967 | 0.77 | XDH (0.52) | XDHIKBKETBK1FNTAFNTB | |
| SCHEMBL5551550 | 0.76 | XDH (0.46) | XDHPPIAFNTAFNTBPGGT1B | |
| SCHEMBL551997 | 0.74 | FNTA (0.53) | XDHSGMS2FNTAFNTBPGGT1B | |
| SCHEMBL13887201 | 0.74 | C5AR1 (0.51) | XDHFNTAFNTBPGGT1B | |
| SCHEMBL8143434 | 0.72 | HPGD (0.54) | XDH | |
| SCHEMBL579571 | 0.72 | OPRM1 (0.61) | JAK3IRAK4HCAR3 | |
| SCHEMBL14607583 | 0.72 | HCAR3 (0.76) | JAK3IRAK4HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | claimed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | claimed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | disclosed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | GSK3B, GSK3A, PHKG1 | XDH 1032/4885SGMS2 2967/4885JAK3 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.